James R. Klinenberg, M.D.; Basil B. Clyman, M.D.; Carl M. Pearson, M.D., F.A.C.P.
This content is PDF only. Please click on the PDF icon to access.
The recent general availability of the xanthine oxidase inhibitor, allopurinol, has resulted in some confusion as to its role in the treatment of gout and other conditions associated with hyperuricemia. General experience from the past suggests that the majority of patients with hyperuricemia respond satisfactorily to treatment with uricosuric agents. Despite the fact that there have been few adverse reactions to allopurinol reported to date, there is still the potential danger of xanthine deposition in the urinary tract after prolonged allopurinol administration. Therefore, specific indications for the use of allopurinol should be defined. Data are presented to support the following
Klinenberg JR, Clyman BB, Pearson CM. Indications for the Use of Allopurinol in the Treatment of Gout and Hyperuricemia.. Ann Intern Med. 1967;66:1059–1060. doi: 10.7326/0003-4819-66-5-1059_3
Download citation file:
Published: Ann Intern Med. 1967;66(5):1059-1060.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use